Structural Characteristics and Anticoagulant Property In Vitro and In Vivo of a Seaweed Sulfated Rhamnan.

Xue Liu,Wenjun Mao,Meijia He,Sujian Cao,Jiejie Hao,Yajing Yang,Ling Qin,Xiaoxi He,Shuyao Wang

doi:10.3390/md16070243

Abstract

Great diversity and metabolite complexity of seaweeds offer a unique and exclusive source of renewable drug molecules. Polysaccharide from seaweed has potential as a promising candidate for marine drug development. In the present study, seaweed polysaccharide (SPm) was isolated from Monostroma angicava, the polymeric repeat units and anticoagulant property in vitro and in vivo of SPm were investigated. SPm was a sulfated polysaccharide which was mainly constituted by 3-linked, 2-linked-α-l-rhamnose residues with partially sulfate groups at C-2 of 3-linked α-l-rhamnose residues and C-3 of 2-linked α-l-rhamnose residues. Small amounts of xylose and glucuronic acid exist in the forms of β-d-Xylp(4SO4)-(1→ and β-d-GlcA-(1→. SPm effectively prolonged clotting time as evaluated by the activated partial thromboplastin time and thrombin time assays, and exhibited strong anticoagulant activity in vitro and in vivo. The fibrin(ogen)olytic and thrombolytic properties of SPm were evaluated by plasminogen activator inhibitior-1, fibrin degradation products, D-dimer and clot lytic rate assays using rats plasma, and the results showed that SPm possessed high fibrin(ogen)olytic and thrombolytic properties. These results suggested that SPm has potential as a novel anticoagulant agent.

Highlights

Thrombotic diseases are reported to contribute to 30% early deaths globally [1,2]
High performance gel permeation chromatography (HPGPC) analysis of SPm gave a homogeneous profile with molecular weight of
High performance liquid chromatography (HPLC) analysis showed that SPm contained rhamnose as the major sugar (85.60 mol%), together with xylose (6.39 mol%) and glucuronic acid (8.01 mol%)

Summary

Introduction

Thrombotic diseases are reported to contribute to 30% early deaths globally [1,2]. Anticoagulant drugs have been extensively used as an adjunct therapy in thrombotic diseases, and heparin is the initial choice. Heparin has adverse events, including development of thrombocytopenia, hemorrhagic effect, and ineffectiveness in congenital or acquired anthrombin deficiencies [3,4]. The incidenc of prion-related diseases in mammals and the increasing requirement of anticoagulant therapy demonstrate that it is necessary to look for alterative sources of anticoagulant agents [5,6,7,8]. Seaweeds are a huge source of natural products owing to their specific marine environment [9,10]

Methods

Results

Conclusion